Serum biomarkers of immunomodulation during peanut epicutaneous immunotherapy (epit) in peanut-allergic subjects

In a Phase 3, randomized, double-blind, placebo-controlled trial in children 4-11 years, daily EPIT with 250 µg peanut patch (VP-250) was superior to placebo (p = 0.00001) in proportion of responders (based on peanut double-blind, placebo-controlled food challenge threshold change) after application for 12 months. We evaluated biomarkers differentiating VP-250 vs. placebo subjects.

https://www.annallergy.org/article/S1081-1206(18)30781-6/fulltext?rss=yes

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Greenhawt, W. Carr, C. Davis, J. Lieberman, S. Mustafa, T. Green, P. Gramme, R. Lambert, D. Fleischer Tags: A305 Source Type: research